Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo‐angiogenesis regulation
Antonio Mazzocca, Emilia Fransvea, Gabriela Lavezzari, Salvatore Antonaci, Gianluigi Giannelli – 28 September 2009 – Curative therapies for patients with hepatocellular carcinoma (HCC) are mainly invasive, and with the exception of sorafenib, no medical treatments are available for advanced or metastatic stages of HCC. We investigated the antitumoral effect of blocking the transforming growth factor β (TGF‐β) signaling pathway in HCC with LY2109761, a kinase inhibitor of TGF‐β receptor I kinase.